NAS:IMAB (China)  
I-MAB logo

I-MAB

$ 6.80 +0.39 (+6.08%) 10:08 PM EST
P/E:
At Loss
P/B:
0.94
Market Cap:
$ 565.08M
Enterprise V:
$ 2.28M
Volume:
385.19K
Avg Vol (2M):
692.68K
Also Trade In:
Volume:
385.19K
Market Cap $:
565.08M
PE Ratio:
At Loss
Avg Vol (2-Month):
692.68K
Enterprise Value $:
2.28M
PB Ratio:
0.94

Business Description

Description
I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will be felzartamab for the China market, a CD38 inhibitor for multiple myeloma, which we estimate will be launched in late 2023 or early 2024. Core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor; uliledlimab, a potential best-in-class CD73 inhibitor; and eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature.
Name Current Vs Industry Vs History
Cash-To-Debt 37.77
Equity-to-Asset 0.81
Debt-to-Equity 0.03
Debt-to-EBITDA -0.05
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 1/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0.52
Distress
Grey
Safe
Beneish M-Score 2.25
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 63.07
9-Day RSI 64.05
14-Day RSI 64.67
6-1 Month Momentum % -69.53
12-1 Month Momentum % -84.39

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 7.31
Quick Ratio 7.31
Cash Ratio 6.65
Days Inventory 137.42
Days Sales Outstanding 51.23

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -21.5